Eligibility criteria summarized across 24 first-line phase 3 clinical trials and 10 clinicaltrials.gov trials in follicular lymphoma
| Variables . | Phase 3 clinical trials, n (%) . | Phase 2-3 clinicaltrials.gov trials, n (%) . |
|---|---|---|
| Stage/extent of disease | 21 (88) | 9 (90) |
| Renal function | 21 (88) | 3 (30) |
| HIV/AIDS status | 20 (83) | 6 (60) |
| Performance status | 19 (79) | 7 (70) |
| History of other malignancies | 19 (79) | 4 (40) |
| Hepatic function | 19 (79) | 3 (30) |
| Cardiac function | 17 (71) | 1 (10) |
| Treatment required for disease | 15 (63) | |
| Grade | 14 (58) | |
| Pregnancy status | 13 (54) | 8 (80) |
| Neuro/psych function | 13 (54) | |
| Metabolic disease | 12 (50) | |
| Birth control use | 12 (50) | |
| Pulmonary function | 12 (50) | |
| Self-reported serious medical conditions | 12 (50) | 5 (50) |
| CNS involvement | 11 (46) | |
| WBC requirement | 11 (46) | |
| HBV status | 10 (42) | 3 (30) |
| Platelet requirement | 10 (42) | 8 (80) |
| Absence of FL transformation | 10 (42) | |
| Measurable disease | 9 (38) | |
| CD20 positivity | 9 (38) | |
| HCV status | 8 (33) | 2 (20) |
| Active infection status | 8 (33) | 3 (30) |
| Life expectancy | 8 (33) | |
| Breastfeeding status | 8 (33) | |
| No concurrent trial registration | 5 (21) | 5 (50) |
| Hemoglobin requirement | 4 (17) | 1 (10) |
| On study within 3 mo of diagnosis | 3 (13) | |
| No major surgery within 28 d | 3 (13) | |
| Tissue diagnosis within 12 mo | 2 (8) | |
| Histologic exam within 6 mo | 1 (4) |
| Variables . | Phase 3 clinical trials, n (%) . | Phase 2-3 clinicaltrials.gov trials, n (%) . |
|---|---|---|
| Stage/extent of disease | 21 (88) | 9 (90) |
| Renal function | 21 (88) | 3 (30) |
| HIV/AIDS status | 20 (83) | 6 (60) |
| Performance status | 19 (79) | 7 (70) |
| History of other malignancies | 19 (79) | 4 (40) |
| Hepatic function | 19 (79) | 3 (30) |
| Cardiac function | 17 (71) | 1 (10) |
| Treatment required for disease | 15 (63) | |
| Grade | 14 (58) | |
| Pregnancy status | 13 (54) | 8 (80) |
| Neuro/psych function | 13 (54) | |
| Metabolic disease | 12 (50) | |
| Birth control use | 12 (50) | |
| Pulmonary function | 12 (50) | |
| Self-reported serious medical conditions | 12 (50) | 5 (50) |
| CNS involvement | 11 (46) | |
| WBC requirement | 11 (46) | |
| HBV status | 10 (42) | 3 (30) |
| Platelet requirement | 10 (42) | 8 (80) |
| Absence of FL transformation | 10 (42) | |
| Measurable disease | 9 (38) | |
| CD20 positivity | 9 (38) | |
| HCV status | 8 (33) | 2 (20) |
| Active infection status | 8 (33) | 3 (30) |
| Life expectancy | 8 (33) | |
| Breastfeeding status | 8 (33) | |
| No concurrent trial registration | 5 (21) | 5 (50) |
| Hemoglobin requirement | 4 (17) | 1 (10) |
| On study within 3 mo of diagnosis | 3 (13) | |
| No major surgery within 28 d | 3 (13) | |
| Tissue diagnosis within 12 mo | 2 (8) | |
| Histologic exam within 6 mo | 1 (4) |